Al Qassimi Hospital Launches Advanced AI Heart Imaging System in Middle East

Sharjah's Al Qassimi Hospital has activated a cardiac imaging platform that advances how heart specialists detect arterial disease. The Ultreon 3.0 system, developed by Abbott and deployed in early April at the Emirates Health Services facility, combines optical coherence tomography with artificial intelligence to visualize coronary blockages with high clarity—capturing the complete internal structure of an artery in a single second, without injecting contrast dye, and analyzing blood-flow restrictions with approximately 82% greater precision than traditional approaches. For residents and expatriates living in the UAE, where cardiovascular disease ranks as the leading cause of mortality, this capability translates into more accurate diagnosis, safer procedures, and better long-term survival prospects.

Why This Matters

• Contrast-free imaging protects vulnerable patients: Diabetics, kidney-disease sufferers, and those allergic to iodine now avoid contrast-induced kidney damage and allergic reactions—complications that can require dialysis or hospitalization. This eliminates a significant procedural risk for patients with these conditions.

• One-visit decision-making replaces guesswork: Cardiologists now combine detailed plaque mapping, vessel dimensions, and functional blood-flow measurement in a single procedure, eliminating the need for follow-up testing to decide whether a narrowing requires stenting. This cuts procedure volume, radiation exposure, and the emotional toll of repeat hospital visits.

• Access through public healthcare network: Ultreon 3.0 is now available at Al Qassimi Hospital within the Emirates Health Services network, bringing advanced imaging technology to government-insured Emiratis and expatriate workers with standard coverage at a public-sector facility.

• Stent placement precision reduces lifetime complications: Optimized positioning of coronary stents reduces the risk of restenosis (renarrowing) and thrombosis (clotting) over years, lowering the cumulative burden of repeat interventions and hospitalizations.

Understanding the Technology

Traditional coronary angiography resembles tracing blockages in a garden hose from the outside—you see the obstruction but miss critical detail about its composition. Ultreon 3.0 inserts an extremely thin fiber directly into the artery and fires near-infrared light into the vessel wall, analyzing the reflections to construct a cross-sectional map of the arterial architecture. This reveals not merely how narrow an artery is, but the type of obstruction: soft fatty plaque vulnerable to rupture, calcified mineral deposits requiring specialized removal equipment, or stable scar tissue unlikely to cause problems.

The embedded artificial intelligence processes this visual data automatically. It aligns the high-resolution images with traditional X-ray angiography, calculates fractional flow reserve—essentially measuring whether a specific narrowing actually starves the heart muscle of blood during exertion—and flags lipid-rich plaques that merit aggressive treatment to prevent future heart attacks. No additional steps, no extra catheters, no prolonged procedure time.

Dr. Arif Al-Nouriani, who leads the Al Qassimi Heart Centre, describes the deployment as a significant development in coronary diagnosis. His clinical team has already treated two Emirati patients using the system, with early results demonstrating both diagnostic reliability and operational efficiency. The entire imaging sequence completes in less than one second—a meaningful distinction when minimizing patient discomfort, radiation accumulation, and workflow congestion in the catheterization laboratory.

Regional Context

The Gulf's cardiac imaging market is expanding at approximately 9.5% annually, projected to exceed USD 15 million by 2033. This growth mirrors demographic reality: cardiovascular disease remains the UAE's primary killer. Concurrently, government-mandated healthcare expansion and UAE Vision 2021 targets to reduce cardiac mortality are fueling substantial infrastructure spending.

Al Qassimi's adoption makes it one of the first public hospitals in the region to deploy OCT with embedded AI. Other regional centers like Cleveland Clinic Abu Dhabi and Sheikh Shakhbout Medical City have invested in cardiac MRI and multi-detector CT scanning—excellent for initial diagnosis but lacking the vessel-wall detail OCT provides during intervention planning. Allied Medical Center in Dubai offers comprehensive CT angiography and cardiac MRI services. Across borders, Clemenceau Medical Center in Beirut deploys FFR-CT, a non-invasive flow-analysis tool that evaluates stenosis without catheter insertion.

Global device manufacturers—Abbott, Medtronic, Boston Scientific, GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems—compete through clinical evidence generation, product innovation, and regional technical support. Abbott's distinction lies in embedding AI directly into OCT workflow. Competitors like Philips Azurion and Siemens ARTIS icono enhance X-ray angiography itself through 3D rotational imaging and algorithmic radiation reduction, addressing different clinical gaps.

Intravascular ultrasound (IVUS), OCT's primary invasive competitor, uses sound waves instead of light and penetrates deeper into vessel tissue. However, OCT delivers approximately ten times finer axial resolution—critical for visualizing how stents contact artery walls or detecting thin-walled plaques prone to rupture. Routine lesions may adequately respond to IVUS analysis, but complex cases demanding millimeter-level precision favor OCT.

Non-invasive alternatives like coronary CT angiography (CCTA) and coronary MR angiography (CMRA) gain ground for initial workups in lower-risk patients, avoiding catheter insertion entirely. Yet invasive angiography paired with intracoronary imaging remains the gold standard when intervention is planned or diagnostic uncertainty persists after non-invasive testing.

What This Means for Residents

For someone living in the Emirates diagnosed with coronary artery disease or at high cardiac risk, Ultreon 3.0 availability at Al Qassimi Hospital creates immediate, tangible benefits.

Procedural safety improves concretely. Patients over 70, diabetics, and those with marginal kidney function historically faced contrast-induced kidney injury—a serious complication sometimes requiring dialysis. The contrast-free imaging capability largely eliminates this risk. Allergic reactions to iodinated dye disappear entirely, removing a source of anxiety for susceptible individuals.

Treatment decisions become evidence-based rather than interpretive. A cardiologist historically estimated whether a 70% narrowing warranted stenting or could be managed medically. Today, AI-calculated blood-flow measurement and automated plaque composition analysis provide objective guidance. This reduces unnecessary stenting (which carries its own long-term failure risks) while ensuring genuinely symptomatic lesions receive appropriate intervention.

Healthcare outcomes improve through optimized procedures. Optimized stent placement minimizes restenosis and thrombosis over subsequent years. A patient avoiding even one repeat procedure over a decade reduces cumulative radiation exposure and healthcare demand. For those managing multiple chronic conditions, more efficient cardiac procedures frees resources within the healthcare system.

Residents access advanced diagnostic capability at a public facility. Government-insured employees can access this diagnostic precision at Al Qassimi Hospital, an important step in bringing advanced technology into the public healthcare network.

Operational Reality and Implementation

Al Qassimi Hospital serves as the debut site for Ultreon 3.0 in the Middle East region, with Radboudumc in the Netherlands running parallel deployment. The technology is operational, not experimental. Patients referred for coronary angiography can expect access where clinically indicated. No waiting for regulatory approvals or research protocols; the system is embedded in daily workflow.

The hospital's decision to activate this platform reflects broader Emirates Health Services strategy: advancing diagnostic precision through AI integration and positioning the UAE as a regional medical hub. Early adoption of AI-driven diagnostics at public hospitals signals capability to international medical systems and prospective patients seeking treatment in the region.

The deployment may signal potential for comparable AI-enabled imaging expansions to other Emirates Health Services facilities, though no timeline or formal announcements have been made. This measured approach allows training consolidation, real-world data collection, and operational refinement. From a regulatory standpoint, Ultreon 3.0 operates within the established UAE framework for invasive cardiac devices. Software enhancements—moving from earlier OCT generations to AI-augmented analysis—follow conventional approval pathways.

Evidence Foundation and Future Outlook

The foundational research underlying OCT-guided coronary intervention provides strong predictive power for Ultreon 3.0's anticipated benefits. The ILUMIEN IV clinical trial, which tracked thousands of patients undergoing stent placement with OCT guidance versus traditional angiography alone, documented a 64% reduction in stent clotting—the most prevalent cause of stent failure within the first year post-placement. Ultreon 3.0's AI layer is engineered to standardize and amplify these benefits by replacing variable cardiologist interpretation with reproducible, automated analysis. This matters considerably: a patient treated on Monday morning receives equivalent diagnostic precision to one examined Friday afternoon, leveling clinical quality irrespective of timing or individual operator fatigue.

Al Qassimi's role as a regional debut site positions the hospital to contribute real-world outcome data to the medical literature, publish procedural findings, and help establish protocols in the region. Abbott has signaled that Ultreon OCT capabilities will feature prominently at TCT 2025 scientific symposia, emphasizing how AI transforms imaging data into treatment decisions and shapes the future of percutaneous coronary intervention.

The practical timeline for residents is immediate: patients requiring coronary angiography at Al Qassimi have access to this technology now. The longer competitive view hinges on how rapidly rival equipment manufacturers integrate comparable AI into their OCT or IVUS platforms, or whether non-invasive alternatives like advanced CCTA software mature expeditiously. However, early deployment advantages—data accumulation, clinical experience, institutional reputation—typically persist for years beyond initial launch. For a hospital system aiming to establish regional cardiac leadership, this timing represents an important step forward.

For the broader UAE healthcare ecosystem, Ultreon 3.0 represents a significant development. As artificial intelligence becomes routine in imaging interpretation across cardiology, ophthalmology, and allied specialties, expectations may grow that major hospitals integrate comparable capabilities. This adoption pattern that began at Al Qassimi may influence future infrastructure decisions across the Emirates' hospital network, potentially advancing diagnostic capabilities within public-sector facilities.